Civitas Therapeutics
2009
FOUNDED
M&A
STATUS
51-60
EMPLOYEES
M&A
LATEST DEAL TYPE
$525M
LATEST DEAL AMOUNT
Description
Developer of respiratory drug delivery therapies. The company has developed a program in Parkinson's disease that leverages the ARCUS respiratory delivery platform. CVT-301, Civita's other lead program, is being developed for the treatment of debilitating and unpredictable motor fluctuations associated with Parkinson's disease.
Website
Formerly Known As
Corregidor Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Acquirer
Primary Office
- 190 Everett Avenue
- Chelsea, MA 02150
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Civitas Therapeutics’s full profile, request a free trial.
Civitas Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 23-Oct-2014 | $525M | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
| 6. IPO | 23-Oct-2014 | 0000 | 00000 | Cancelled | Clinical Trials - Phase 3 | |
| 5. Later Stage VC (Series C) | 25-Aug-2014 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
| 4. Early Stage VC (Series B) | 11-Sep-2013 | 0000 | 0000 | 00000 | Completed | Clinical Trials - Phase 2 |
| 3. Grant | 18-Jun-2013 | 000 | 0000 | Completed | Clinical Trials - Phase 2 | |
| 2. Grant | $25M | Completed | ||||
| 1. Early Stage VC (Series A) | 12-Jul-2011 | $25M | $25M | 000.00 | Completed | Product Development |
Civitas Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 28,529,412 | $0.001000 | $0.08 | $1 | $1 | 1x | $1 | 27.19% |
Civitas Therapeutics Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 0000000 | Formerly PE-Backed | Hayward, CA | 00 | 00000 | 0000000000. |
Civitas Therapeutics Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| Alkermes | Corporation | Minority | 000 0000 | 000000 0 | ||
| Bay City Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Canaan Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Fountain Healthcare Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Civitas Therapeutics Executive Team (11)
6 Former Executives
You’re viewing 5 of 11 executives. Get the full list »Civitas Therapeutics Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Robert Roche Jr. | Self | Board Member | 000 0000 | |
| Timothy Nelson | Civitas Therapeutics | Chairman | 000 0000 |
6 Former Board Members
You’re viewing 2 of 8 board members. Get the full list »